Related Experiment Video

Updated: Jun 13, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Emerging treatments for the prevention of type 1 diabetes

Philip Raskin1, Alok Mohan

  • 1University of Texas Southwestern Medical Center in Dallas, Department of Endocrinology, 5323 Harry Hines Blvd MC8858, Dallas, Texas 75219, USA.

Expert Opinion on Emerging Drugs
|April 14, 2010
PubMed
Abstract

Insights

New therapeutic strategies are being evaluated for type 1 diabetes (T1D) prevention and treatment. Emerging therapies, including monoclonal antibody treatments, show promise for potentially curing T1D.

Area of Science:

  • Immunology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Type 1 diabetes (T1D) is an autoimmune disease influenced by genetic and environmental factors.
  • Current T1D management relies solely on insulin therapy, highlighting the need for disease-modifying treatments.
  • Understanding beta-cell destruction is crucial for developing novel therapeutic interventions.

Purpose of the Study:

  • To review current strategies for T1D prevention and treatment.
  • To present data on the efficacy and safety of emerging T1D therapies.
  • To explore the potential of new drugs in achieving a cure for T1D.

Main Methods:

  • Review of various therapeutic agents and strategies for T1D.
  • Evaluation of environmental factor modifications.
  • Assessment of monoclonal antibody (mAb) therapies, including otelixizumab, rituximab, and abatacept.
  • Consideration of other agents such as Diapep 277 and GAD65.

Main Results:

  • Several promising strategies for T1D intervention are under investigation.
  • Data on the efficacy and safety profiles of emerging T1D drugs are presented.
  • New therapeutic agents offer potential for disease modification and prevention.

Conclusions:

  • Emerging therapies may offer new avenues for T1D research and treatment.
  • Some novel drugs could potentially lead to a cure for T1D.
  • These advancements offer hope for millions affected by T1D globally.

More Related Videos

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice10:03

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...